SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson Fistel, LLP is investigating potential claims
against Bioverativ Inc., and Juno Therapeutics, Inc., as detailed
below:
Bioverativ Inc.
Shareholder rights law firm Johnson
Fistel, LLP has launched an investigation into whether the board
members of Bioverativ Inc. (NASDAQ: BIVV) ("Bioverativ ") breached
their fiduciary duties in connection with the proposed sale of the
Company to Sanofi (NYSE: SNY).
On January 22, 2018, Bioverativ
announced that it had signed a definitive merger agreement with
Sanofi. Under the terms of the agreement, Sanofi will acquire all
of the outstanding shares of Bioverativ for $105 per share in cash.
The investigation concerns whether the Bioverativ board failed
to satisfy its duties to the Company shareholders, including
whether the board adequately pursued alternatives to the
acquisition and whether the board obtained the best price possible
for Bioverativ shares of common stock, especially given the
Company's projected revenue and earnings growth.
If you are a shareholder of Bioverativ and believe the
proposed buyout price is too low or you're interested in learning
more about the investigation or your legal rights and remedies,
please contact lead analyst Jim
Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing,
please include a phone number.
.
Juno Therapeutics, Inc.
Shareholder rights law firm
Johnson Fistel, LLP has launched an investigation into whether the
board members of Juno Therapeutics, Inc. (NASDAQ: JUNO) ("Juno")
breached their fiduciary duties in connection with the proposed
sale of the Company to Celgene Corporation.
On January 22, 2018, Juno
announced that it had signed a definitive merger agreement with
Celgene. Under the terms of the agreement, Celgene will acquire all
of the outstanding shares of Juno for $87 per share in cash.
The investigation concerns whether the Juno board failed to
satisfy its duties to the Company shareholders, including whether
the board adequately pursued alternatives to the acquisition and
whether the board obtained the best price possible for Juno shares
of common stock. Nationally recognized Johnson Fistel is investigating whether the
proposed deal represents adequate consideration, especially given
that the one Wall Street analyst has a $98.00 price target on the stock.
If you are a shareholder of Juno and believe the
proposed buyout price is too low or you're interested in learning
more about the investigation or your legal rights and remedies,
please contact lead analyst Jim
Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing,
please include a phone number.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
View original
content:http://www.prnewswire.com/news-releases/johnson-fistel-announces-investigations-of-the-proposed-sales-of-bioverativ-inc-and-juno-therapeutics-inc-300585805.html
SOURCE Johnson Fistel, LLP